M. Alexander and H. Moses, Transforming growth factor b and cell cycle regulation, Cancer Res, vol.55, pp.1452-1457, 1995.

K. Bajou, C. Maillard, M. Jost, R. Lijnen, A. Gils et al., Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth, Oncogene, vol.23, issue.41, pp.6986-6990, 2004.
DOI : 10.1038/sj.onc.1207859

E. Bottinger, J. Jakubczak, D. Haines, K. Bagnall, and L. Wakefield, Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene, Cancer Res, vol.57, pp.5564-5570, 1997.

R. Bristow, R. Baldwin, S. Yamada, M. Korc, and B. Karlan, Altered expression of transforming growth factor-? ligands and receptors in primary and recurrent ovarian carcinoma, Cancer, vol.56, issue.3, pp.658-668, 1999.
DOI : 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M

D. Chakravarthy, A. Green, V. Green, M. Kerin, and V. Speirs, Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast., International Journal of Oncology, vol.15, pp.187-194, 1999.
DOI : 10.3892/ijo.15.1.187

T. Chen, D. Carter, L. Garrigue-antar, and M. Reiss, Transforming growth factor-b type I receptor kinase mutant associated with metastatic breast cancer, Cancer Res, vol.58, pp.4805-4810, 1998.

B. Dalal, P. Keown, and A. Greenberg, Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node matastases of human mammary carcinoma, Am J Pathol, vol.143, pp.381-389, 1993.

E. Dublin, D. Barnes, D. Wang, R. King, and D. Levison, TGF alpha and TGF beta expression in mammary carcinoma, The Journal of Pathology, vol.5, issue.1, pp.15-22, 1993.
DOI : 10.1002/path.1711700104

M. Duffy, C. Duggan, H. Mulcahy, E. Mcdermott, O. Higgins et al., Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease, Clin Chem, vol.44, pp.1177-1183, 1998.

J. Foekens, H. Portengen, W. Van-putten, A. Trapman, J. Reubi et al., Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast cancer tumor cytosol, Cancer Res, vol.49, pp.5823-5828, 1989.

J. Foekens, R. S. Look, M. Martin, P. Klijn, and J. , Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy, Cancer Res, vol.61, pp.1421-1425, 2001.

Y. Fukai, M. Fukuchi, N. Masuda, H. Osawa, H. Kato et al., Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human oesophageal squamous cell carcinoma, Int J Cancer, vol.20, pp.161-166, 2003.

A. Ghellal, C. Li, M. Hayes, G. Byrne, N. Bundred et al., Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma, Anticancer Res, vol.20, pp.4413-4418, 2000.

H. Gobbi, C. Arteaga, R. Jensen, J. Simpson, W. Dupont et al., Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas, Histopathology, vol.21, issue.2, pp.168-177, 2000.
DOI : 10.1126/science.282.5397.2270

S. Gorsch, V. Memoli, T. Stukel, L. Golg, and B. Arrick, Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer, Cancer Res, vol.52, pp.6949-6952, 1992.

W. Grady, L. Myeroff, S. Swinler, A. Rajput, S. Thiagalingam et al., Mutational inactivation of transforming growth factor b receptor type II in microsatellite stable cancer colon, Cancer Res, vol.59, pp.320-324, 1999.

V. Ivanovic, A. Melman, D. , B. Valvic, M. Geliebter et al., Elevated plasma levels of TGF-??1 in patients with invasive prostate cancer, Nature Medicine, vol.87, issue.4, pp.282-284, 1995.
DOI : 10.1210/me.6.1.15

V. Ivanovic, N. Todorovic-rakovic, M. Demajo, Z. Neskovic-konstantinovic, V. Subota et al., Elevated plasma levels of transforming growth factor-??1 (TGF-??1) in patients with advanced breast cancer: association with disease progression, European Journal of Cancer, vol.39, issue.4, pp.454-461, 2003.
DOI : 10.1016/S0959-8049(02)00502-6

J. Jeruss, C. Sturgis, A. Rademaker, and T. Woodruff, Downregulation of activin, activin receptors, and smads in high-grade breast cancer, Cancer Res, vol.63, pp.3783-3790, 2003.

C. Jhappan, A. Geiser, E. Kordon, D. Bagheri, L. Hennighausen et al., Targeting expression of a transforming growth factor b1 transgene to the pregnant mammary gland inhibits alveolar development and lactation, EMBO J, vol.12, pp.1835-1845, 1993.

A. Kesari, V. Chellam, B. Mathew, M. Nair, and M. Pillai, Transforming growth factor beta related to extent of tumo angiogenesis but not apoptosis or proliferation in breast carcinoma, Breast Cancer, vol.25, pp.29-36, 1999.

C. Knabbe, M. Lippman, L. Wakefield, K. Flanders, A. Kasid et al., Evidence that transforming growth factor-?? is a hormonally regulated negative growth factor in human breast cancer cells, Cell, vol.48, issue.3, pp.417-428, 1987.
DOI : 10.1016/0092-8674(87)90193-0

F. Kong, M. Anscher, T. Murase, B. Abbott, J. Iglehart et al., Elevated Plasma Transforming Growth Factor-??1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor, Annals of Surgery, vol.222, issue.2, pp.155-162, 1995.
DOI : 10.1097/00000658-199508000-00007

A. Lebrecht, C. Grimm, G. Euller, E. Ludwig, E. Ulbrich et al., Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast, The International Journal of Biological Markers, vol.19, issue.3, pp.236-239, 2004.
DOI : 10.5301/JBM.2008.2143

J. Letterio and A. Roberts, REGULATION OF IMMUNE RESPONSES BY TGF-??, Annual Review of Immunology, vol.16, issue.1, pp.137-161, 1998.
DOI : 10.1146/annurev.immunol.16.1.137

M. Look, W. Van-putten, M. Duffy, N. Harbeck, I. Christensen et al., Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.116-128, 2002.
DOI : 10.1093/jnci/94.2.116

T. Maliekal, M. Antony, A. Nair, R. Paulmurugan, and D. Karunagaran, Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer, Oncogene, vol.22, issue.31, pp.4889-4897, 2003.
DOI : 10.1038/sj.onc.1206806

S. Moretti, C. Pinzi, A. Spallanzani, E. Berti, A. Chiarugi et al., Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions, Int J Cancer, vol.20, pp.160-168, 1999.

P. Murray, P. Barrett-lee, M. Travers, Y. Luqmani, T. Powles et al., The prognostic significance of transforming growth factors in human breast cancer, British Journal of Cancer, vol.67, issue.6, pp.1408-1412, 1993.
DOI : 10.1038/bjc.1993.261

M. Oft, J. Peli, C. Rudaz, H. Schwarz, H. Beug et al., TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells., Genes & Development, vol.10, issue.19, pp.2462-2477, 1996.
DOI : 10.1101/gad.10.19.2462

S. Oh, T. Seki, K. Goss, T. Imamura, Y. Yi et al., Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis, Proceedings of the National Academy of Sciences, vol.196, issue.2, pp.2626-2631, 2000.
DOI : 10.1002/aja.1001960207

R. Perlman, W. Schiemann, M. Brooks, H. Lodish, and R. Weinberg, TGF-b-induced apoptosis is mediated by the adaptor protein DAXX that facilitates JNK activation, Nat Cell Biol, vol.13, pp.708-714, 2001.

N. Philips and K. Mcfadden, Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells, Cancer Letters, vol.206, issue.1, pp.63-68, 2004.
DOI : 10.1016/j.canlet.2003.10.019

A. Picon, L. Gold, J. Wang, A. Cohen, and E. Friedman, A subset of metastasis human colon cancers expresses elevated levels of transforming growth factor beta1, Cancer Epidemiol Biomarkers Prev, vol.7, pp.497-504, 1998.

P. Jr, D. Gorska, A. Chytil, A. Meise, K. Page et al., Mammary tumor suppression by transforming growth factor b1 transgene expression, Proc Natl Acad Sci, vol.92, pp.4254-4258, 1995.

A. Roberts, M. Sporn, S. Romain, C. Lainé-bidron, P. Martin et al., The transforming growth factor-bs In Peptide Growth Factors and their Receptors, Part I Sprone MB Steroid receptor distribution in 47892 breast cancers. A collaborative study of 7 European laboratories, Eur J Cancer, vol.31, pp.419-472, 1990.

S. Romain, F. Spyratos, F. Descotes, A. Daver, B. Rostaing-puissant et al., Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study, International Journal of Cancer, vol.75, issue.6, pp.860-868, 2000.
DOI : 10.1002/1097-0215(20000915)87:6<860::AID-IJC16>3.0.CO;2-Y

A. Schrohl, M. Holten-andersen, H. Peters, M. Look, M. Meijer-van-gelder et al., Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer, Clinical Cancer Research, vol.10, issue.7, pp.2289-2298, 2004.
DOI : 10.1158/1078-0432.CCR-03-0360

I. Schwarte-waldhoff, O. Volpert, N. Bouck, B. Sipos, S. Hahn et al., Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis, Proceedings of the National Academy of Sciences, vol.7, issue.1, pp.9624-9629, 2000.
DOI : 10.1016/S1359-6101(99)00012-X

S. Shariat, M. Kattan, E. Traxel, B. Andrews, K. Zhu et al., Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor ??1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression, Clinical Cancer Research, vol.10, issue.6, pp.1992-1999, 2004.
DOI : 10.1158/1078-0432.CCR-0768-03

R. Strange, F. Li, S. Saurer, A. Burkhardt, and R. Friis, Apoptotic cell death and tissue remodelling during mouse mammary gland involution, Development, vol.115, pp.49-58, 1992.

H. Tsushima, S. Kawata, S. Tamura, N. Ito, Y. Shirai et al., High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression, Gastroenterology, vol.110, issue.2, pp.375-382, 1996.
DOI : 10.1053/gast.1996.v110.pm8566583

L. Wakefield, J. Letterio, T. Chen, D. Danielpour, R. Allison et al., Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer, Clin Cancer Res, vol.1, pp.129-136, 1995.

L. Wakefield, E. Piek, and E. Bottinger, TGF-b signaling in mammary gland development and tumorigenesis, Journal of Mammary Gland Biology and Neoplasia, vol.6, issue.1, pp.67-82, 2000.
DOI : 10.1023/A:1009568532177

R. Walker, S. Dearing, and B. Gallacher, Relationship of transforming growth factor ??1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma, British Journal of Cancer, vol.69, issue.6, pp.1160-1165, 1994.
DOI : 10.1038/bjc.1994.228

D. Wang, T. Kanuma, H. Mizunuma, F. Takama, Y. Ibuki et al., Analysis of specific gene mutations in the transforming growth factor-b signal transduction pathway in human ovarian cancer, Cancer Res, vol.60, pp.4507-4512, 2000.

W. Jr, D. Hopkins, W. Billadello, and J. , Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells, J Biol Chem, vol.266, pp.1092-1100, 1991.

W. Xie, J. Mertens, D. Reiss, D. Rimm, R. Camp et al., Alterations of smad signaling in human breast carcinoma are associated with poor outcome. A tissue microarray study, Cancer Res, vol.62, pp.497-505, 2002.